100% Tariff on Generics to Squeeze Supply: 3-5 Year Reshoring Gap Leaves U.S. Vulnerable
The impending 100% tariff on imported generic drugs could trigger widespread product discontinuations, as thin margins and pricing constraints block pass-through costs. With three to five years needed to build FDA-approved plants, supply chain disruptions are inevitable. The analysis explores manufacturing dependencies and risk exposure.